Rystiggo
Drug
UCB SA
Total Payments
$3.2M
Transactions
12,166
Doctors
3,622
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.1M | 11,736 | 3,615 |
| 2023 | $1.1M | 430 | 41 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 89 | 55.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $699,280 | 261 | 21.9% |
| Consulting Fee | $325,103 | 213 | 10.2% |
| Food and Beverage | $285,611 | 10,971 | 8.9% |
| Travel and Lodging | $101,220 | 632 | 3.2% |
Payments by Type
Research
$1.8M
89 transactions
General
$1.4M
12,077 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) | UCB SA | $742,733 | 0 |
| AN OPEN-LABEL EXTENSION STUDY TO EVALUATE ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | UCB SA | $581,862 | 0 |
| AN OPEN-LABEL, CROSSOVER STUDY TO EVALUATE ROZANOLIXIZUMAB SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS | UCB SA | $284,762 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH LEUCINE-RICH GLIOMA INACTIVATED 1 AUTOIMMUNE ENCEPHALITIS | UCB SA | $154,279 | 0 |
| AN OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN STUDY PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) | UCB SA | $6,000 | 0 |
| A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) | UCB SA | $4,726 | 0 |
| A RANDOMIZED, OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ROZANOLIXIZUMAB IN ADULT PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS | UCB SA | $3,190 | 0 |
| A PHASE 3 MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) | UCB SA | $2,975 | 0 |
Top Doctors Receiving Payments for Rystiggo
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winston-Salem, NC | $1.8M | 130 |
| , MD | Neurology | Phoenix, AZ | $61,345 | 75 |
| , M.D | Neurology | Winchester, VA | $55,317 | 104 |
| , MD | Neurology | Mobile, AL | $45,934 | 36 |
| , MD | Neurology | Downers Grove, IL | $40,025 | 54 |
| , M.D | Neurology | Rancho Mirage, CA | $38,422 | 61 |
| , M.D | Neurology | Los Angeles, CA | $37,561 | 37 |
| , MD | Neuromuscular Medicine | Austin, TX | $36,809 | 55 |
| , MD | Neuromuscular Medicine | Orange, CA | $34,875 | 24 |
| , MD | Neurology | Seattle, WA | $29,453 | 22 |
| , MD | Neuromuscular Medicine | St Petersburg, FL | $27,755 | 38 |
| , MD | Specialist | Hackensack, NJ | $26,882 | 38 |
| , MD | Neurology | O Fallon, IL | $26,395 | 37 |
| , M.D | Neurology | Buffalo, NY | $25,477 | 27 |
| , M.D | Neurology | Houston, TX | $25,107 | 38 |
| , M.D | Neuromuscular Medicine | Chattanooga, TN | $24,066 | 18 |
| , MD | Neurology | Macon, GA | $23,419 | 35 |
| , M.D | Student in an Organized Health Care Education/Training Program | Fenton, MO | $22,887 | 24 |
| , M.D | Neurology | Winston Salem, NC | $22,421 | 33 |
| , M.D., MS | Neurology | East Lansing, MI | $21,306 | 27 |
| , DO | Neurology | Centerville, OH | $21,295 | 36 |
| , MD | Neurology | Burlington, VT | $20,590 | 8 |
| , MD | Neurology | Audubon, NJ | $19,618 | 25 |
| , M.D., PHD | Internal Medicine | Rochester, MN | $19,358 | 9 |
| , MD | Student in an Organized Health Care Education/Training Program | Houston, TX | $18,145 | 25 |
About Rystiggo
Rystiggo is a drug associated with $3.2M in payments to 3,622 healthcare providers, recorded across 12,166 transactions in the CMS Open Payments database. The primary manufacturer is UCB SA.
Payment data is available from 2023 to 2024. In 2024, $2.1M was paid across 11,736 transactions to 3,615 doctors.
The most common payment nature for Rystiggo is "Unspecified" ($1.8M, 55.8% of total).
Rystiggo is associated with 8 research studies, including "A randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD)" ($742,733).